Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novo Nordisk (NVO – Research Report) and ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...

Novo Nordisk has an analyst consensus of Hold, with a price target consensus of $84.83. According to TipRanks.com, Walton is ranked #6629 out of 9418 analysts. Sanofi has an analyst consensus of ...

Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, ...

Hundreds of lawsuits allege that insulin manufacturers and pharmacy benefit managers colluded to raise prices. The ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...

Evotec’s cost-cutting drive has reached its pipeline. The company axed around 30% of its asset portfolio and offloaded ...

Pharma companies are leveraging the United States’ threat of tariffs on drug imports to push for policy changes in the EU. | ...

The U.S. Veterans Administration measures a substantial reduction in its carbon footprint associated with patient travel by ...